Yuvraj

Eli Lilly has agreed to acquire in vivo CAR-T developer Orna Therapeutics in a deal worth up to $2.4 billion, marking another rapid move...

QIAGEN’s QuantiFERON-TB Gold Plus shows cost-effectiveness compared with TST in a newly published study in people with HIV Peer-reviewed health-economic analysis evaluates tuberculosis infection...

Roche announced late-breaking Phase III data showing that fenebrutinib reduces disability progression in PPMS, marking the first investigational advance for primary progressive multiple sclerosis...

Innovent Biologics has announced a strategic Innovent-Lilly partnership with Eli Lilly and Company to advance the global development of new medicines in oncology and...

Deep dive into the convergence of medical engineering and pharmaceutical science, focusing on how integrated delivery systems enhance dosing accuracy and patient outcomes.

Exploration of how computational modeling, high-throughput screening, and digital twins are revolutionizing the pharmaceutical R&D process to optimize formulation efficiency.

GSK’s new chief executive, Luke Miels, said the drugmaker will prioritise faster drug development as it enters its next phase of growth, with a...